ChartRow logo
VRTX
Vertex Pharmaceuticals IncorporatedStock · Healthcare · Nasdaq-100 0.6% · S&P 500 0.2%
$528.19+$12.64 (+2.45%)as of market close, Aug 18, 2026
☾ After hours:$528.19+0.00%7:57 PM ET
CompareLLYUNHJNJISRGABBVTMO

VRTX financial statements

The full income statement, balance sheet, and cash-flow statement for Vertex Pharmaceuticals Incorporated (VRTX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Shares outstanding (point-in-time)

2024-06 258.1M2024-09 257.5M2024-12 256.8M2025-03 256.8M2025-06 256.4M2025-09 253.7M2025-12 254.0M2026-03 253.8M2026-06 253.5M-1.8% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

About this data

Source: VRTX's SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn't file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all VRTX filings on SEC EDGAR → Not investment advice.